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Acute rejection (AR) is a dominant risk factor for developing
chronic allograft nephropathy (CAN) after kidney
transplantation. CAN is characterized by progressive
interstitial fibrosis. It has been associated with increased
transforming growth factor (TGF)-b1 expression, however,
kinetic studies are absent. We investigated whether intragraft
TGF-b1 expression in various causes of early graft
dysfunction may influence late renal allograft dysfunction.
A total of 174 human renal biopsies were quantified
for TGF-b1 mRNA expression using real-time reverse
transcriptase-polymerase chain reaction. Expression levels
were correlated with the Banff histopathological grades,
TGF-b1 immunohistology, and clinical follow-up. TGF-b1 was
most markedly upregulated in AR, CAN, and acute tubular
necrosis – delayed graft function compared to non-rejecting
controls (Po0.001). TGF-b1 expression was heightened in
borderline changes (Po0.01), recurrence of
glomerulonephritis, and cyclosporine toxicity (Po0.05).
There was no correlation between intragraft TGF-b1
expression during AR and short-term outcome of a rejection
episode. TGF-b1 gene overexpression during CAN has been
shown to be associated with the increased risk for renal
allograft dysfunction 18 months after biopsy (odds ratios 9.9
vs 3.2, respectively). Intragraft TGF-b1 mRNA expression is
significantly upregulated in both AR and CAN. Thus, our
results support the hypothesis that TGF-b1 might play a key
role in chronic allograft dysfunction.
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Immunosuppressive agents introduced in the last two
decades have markedly reduced the incidence of acute kidney
allograft rejection and improved the rate of graft survival
during the first year after transplantation.1 This improvement
in early graft survival, however, has not been associated with
a corresponding improvement in the long-term graft
survival.2,3
Chronic allograft nephropathy (CAN) is the most
common cause of long-term allograft dysfunction.2–4 The
pathogenesis of CAN remains to be poorly understood, but
interstitial fibrosis is a major histologic pattern of CAN.5,6
Transforming growth factor (TGF)-b1 contributes to fibro-
genesis in several diseases.7–9 We have recently shown that
genetic predisposition for high production of TGF-b1
because of gene polymorphism in codons 10 and 25 is
associated with the progression of renal insufficiency in heart
transplant recipients.10
TGF-b, a 25-kDa homodimeric peptide, belongs to a
superfamily of homologous growth factors that produce
various effects in different cell types.11 The three numbered
isoforms of TGF-b identified in mammals act as pleiotropic
regulators of cell growth and differentiation, arteriosclerosis
and angiogenesis, immunosuppression, carcinogenesis, in-
flammation, and tissue repair. By multiple mechanisms,
TGF-b1 acts as a major regulator of extracellular matrix
production and degradation;11 it stimulates synthesis of
extracellular matrix (collagen, fibronectin, and proteo-
glycans), enhances expression of integrins, and reduces
activities of matrix-degrading proteases.12–15
Although TGF-b1 expresses immunosuppressive effects by
inhibiting lymphocyte activation, it also plays a proinflam-
matory role in tissues. Consistent with its function in wound
healing and repair, it is chemoattractive for leukocytes.16
Recent studies suggest that TGF-b1 may also have a role
in acute rejection by promoting cell-mediated cytotoxic
damage. TGF-b1 controls the expression of aEb7 integrin on
CD8þ T lymphocytes. The ligand of aEb7 integrin is the
epithelial cell-specific E-cadherin, known to be expressed by
critical graft functional elements such as the renal tubular
epithelium.17–19 It has been suggested that, in the presence of
high levels of TGF-b1, activated T lymphocytes may be
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redirected to tubular epithelial cells, to which they bind
strongly and cause tubulocytolysis.
Previous studies of TGF-b1 expression in renal allograft
biopsies indicated that the presence of interstitial fibrosis
correlated with intragraft expression of TGF-b1. Moreover,
quantitative reverse transcriptase-polymerase chain reaction
(RT-PCR) for TGF-b1 has indicated that hyperexpression of
TGF-b1 correlates with CAN.20–22 The type of immunosup-
pressive therapy influences TGF-b1 intragraft expression.
Interestingly, calcineurin inhibitors such as cyclosporine are
thought to stimulate expression of TGF-b1, leading to
fibrosis. It was suggested that this effect of cyclosporine
may be involved in the pathogenesis of progressive renal
disease.22–24 Furthermore, it was reported that tacrolimus
stimulates TGF-b1 expression as well.25–26 However, kinetic
studies were missing.
Our study was designed to investigate TGF-b1 expression
in human renal allograft biopsies using real-time RT-PCR.
We analyzed TGF-b1 mRNA expression in different causes of
graft dysfunction and followed graft outcome. Here, we show
that high intragraft TGF-b1 mRNA expression predicts
inferior outcome in CAN and may contribute to later renal
graft dysfunction in patients with acute rejection.
RESULTS
Histology
Using the criteria of the Banff 97 classification, 25 specimens
were classified as acute rejections (AR; 12 as grade I, 10 as
grade II and three as grade III; biopsies were performed 4
days to 1.6 years after transplantation with a mean value of 19
days), 15 as ‘borderline changes’, and 48 as CAN. Thirty-one
allograft biopsies showed a normal histological pattern of
renal tissue (no signs of either acute rejection or CAN) with
all these grafts having stable and excellent function. Four
specimens were classified as recurrence of glomerulonephritis
(GN), 14 as acute tubular necrosis – delayed graft function
(ATN), and 11 as cyclosporine A (CsA) toxicity.
Patient data
The clinical characteristics of the patients are listed in Table 1.
Donor age, patient age, gender, occurrence of diabetes
mellitus, occurrence of hypertension, and use of angiotensin
receptor blockers did not differ significantly among patient
groups. There were significantly more patients with a living-
donor kidney transplant in the ATN group, compared to
other patient groups (Po0.05). There was significantly
longer time between transplantation and biopsy in the
CAN and GN groups and significantly shorter in the ATN
group (Po0.05). This corresponds with the character of
these groups (histological findings). The use of angiotensin-
converting enzyme inhibitors was significantly higher in the
CAN and GN groups (Po0.01) and significantly lower in the
AR and ATN groups (Po0.01). Serum creatinine levels at the
time of biopsy were significantly higher in the AR and ATN
groups (Po0.05); estimated glomerular filtration rate (GFR)
at the time of biopsy was significantly lower in the AR and
ATN groups (Po0.001) and the CAN group (Po0.05).
There were significantly more patients with graft dysfunction
(defined as GFR o0.8 ml/s) 18 months after biopsy in the
CAN group (Po0.05) and fewer patients with graft
dysfunction 18 months after biopsy in the ATN group
(Po0.05) compared to other patient groups.
TGF-b1 protein expression during CAN
TGF-b1 protein expression was found in all 81 kidney
allograft biopsies. Total score representing TGF-b1 positivity
in the six assessed renal structures (glomeruli, tubuli,
peritubular capillaries, intima, and interstitium and infiltrat-
Table 1 | Clinical characteristics of the patient groups and the control group
Group Non Rxa B Rxb AR CAN ATN GN CsA. tox
Number of biopsies 31 15 25 48 14 4 11
Gender (female) 12 (39%) 5 (33%) 9 (36%) 14 (29%) 4 (29%) 1 (25%) 0 (0%)
Patient age (years7s.d.) 45713 48711 50711 48712 47717 5379 52714
Donor age (years7s.d.) 47715 36718 38715 41718 49710 2476 48716
Living-donor kidney transplants (%) 6 7 18 6 29c 0 0
Time between transplantation and biopsy (years7s.d.) 1.370.9 0.270.3 0.570.6 3.674.1c c 4.973.7c 2.071.7
Diabetes (%) 16 20 28 15 7 0 9
Hypertension (%) 94 87 80 98 93 100 100
Use of angiotensin-converting enzyme inhibitors (%) 35 40 0d 56d 0d 75d 27
Use of angiotensin receptor blocker (%) 0 0 0 6 0 0 0
Serum creatinine at the time of biopsy (mmol/l7s.d.) 149743 2267121 3617196c 2307108 5587221c 210770 227791
GFR at the time of biopsy (ml/s7s.d.) 1.170.4 0.870.3 0.570.2e 0.870.4c 0.370.1e 0.770.3 0.770.3
Graft dysfunction at the time of biopsyf (%) 30 40 88 50 100 50 55
Graft dysfunction 18 months after biopsyf (%) 35 27 56 67c 21c 50 73
aNon-rejecting control group.
bBorderline changes.
cPo0.05.
dPo0.01.
ePo0.001.
fGraft dysfunction was defined as the GFR o0.8 ml/s.
AR, acute rejection ; ATN, acute tubular necrosis – delayed graft function; CAN, chronic allograft nephropathy; CsA tox, cyclosporine A toxicity ; GFR, glomerular filtration rate;
GN, glomerulonephritis recurrence.
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ing cells) ranged from 1 to 13. We found a significant
difference in TGF-b1 protein expression in kidney trans-
plants with CAN compared with TGF-b1 expression in renal
allografts with normal function (Table 2). TGF-b1 protein
expression was significantly different in the six assessed renal
structures, but we have not found differences between
expression in the glomeruli and peritubular capillaries, tubuli
and infiltrating cells, and in the interstitium and infiltrating
cells. Significant differences between the non-rejecting
control group and other biopsy groups were observed just
for AR in infiltrating cells (Po0.01) and for CAN in the
interstitium (Po0.05) (Figure 1). TGF-b1 protein expression
was also different in the CAN group compared to the group
of biopsy samples with borderline changes in interstitium
and intima (Po0.05). These groups also differed in total
score (Po0.05). Nevertheless, we have not found an
association between TGF-b1 protein expression and TGF-
b1 mRNA expression in the investigated renal structures and
a significant correlation was not demonstrated for TGF-b1
protein expression total score either (Figure 2).
There was no correlation between TGF-b1 mRNA and
protein expression in patients with CAN, AR, and in non-
rejecting controls.
TGF-b1 mRNA expression in AR
TGF-b1 mRNA expression in all kidney allografts was
quantified by real-time RT-PCR. Comparisons among groups
of AR, ‘borderline changes’, CAN, recurrence of GN, ATN,
CsA-toxicity, and non-rejecting controls are shown in
Figure 3.
We detected a low degree of expression of TGF-b1 mRNA
in kidney allografts with a normal histological pattern of
Table 2 | TGF-b1 protein expression (immunohistology) in
kidney allografts
TGF-b1 protein
expression (total
score) mean7s.d.
Comparison with
control groupa
Non-rejecting controls
(n=12)
5.2573.36 —
Borderline changes (n=10) 5.1071.79 NS
Acute rejection (n=16) 7.1974.14 NS
CAN (n=21) 7.9072.96 Po0.05
ATN (n=10) 7.8074.39 NS
Recurrence of GN (n=4) 5.2573.35 NS
CsA toxicity (n=8) 7.1372.95 NS
Immunohistology of renal tissue showed significant overexpression of TGF-b1
during chronic allograft nephropathy compared with controls. Only a trend to
enhanced TGF-b1 expression during acute rejection, delayed graft function (ATN),
and cyclosporine toxicity (CsA toxicity) was found.
CAN, chronic allograft nephropathy; GN, glomerulonephritis recurrence; TGF-b,
transforming growth factor-b.
aStatistical analysis was performed with Mann–Whitney test. NS, –not significant.
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Figure 1 | TGF-b1 protein expression in different renal structures.
TGF-b1 protein expression level of group CAN was in interstitium
significantly (Po0.05) different from interstitium TGF-b1 protein
expression level of non-rejecting controls. There was difference in
TGF-b1 protein expression levels in infiltrating cells between groups
acute rejection and non-rejecting controls (Po0.01). The boxes show
the average contribution of different renal structures to the total
score of TGF-b1 protein expression. non Rx, non-rejecting controls; a
Rx, acute rejection; b Rx, borderline changes.
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Figure 2 | Trend towards higher TGF-b1 protein expression in
patients with enhanced TGF-b1 mRNA expression. The correlation
coefficient did not reach the level of significance.
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Figure 3 | TGF-b1 mRNA upregulation in different causes of graft
dysfunction. Results are expressed as a ratio in arbitrary units (AU)
TGF-b1/AU HPRT. The mRNA TGF-b1 expression levels of the groups
acute rejection (acute Rx, Po0.001), CAN (Po0.001), ATN (Po0.001),
borderline changes (b Rx, Po0.01), and cyclosporine A toxicity (CsA
tox., Po0.05) were significantly different from the non-rejecting
controls (non Rx). The box plots show the 25th and 75th (boundaries
of boxes), 50th (median), 10th and 90th (error bars), and 5th and 95th
(dots) percentile values.
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renal tissue. The receiver-operating characteristic (ROC)
curve analysis showed that TGF-b1 mRNA expression below
20 indicates normal histological findings with 70% sensitivity
and 73% specificity (area under the curve 0.75, data not
shown). Significantly enhanced TGF-b1 gene expression was
detected in allograft tissue during AR compared to controls.
In acute rejecting grafts, TGF-b1 was overexpressed, being 2.3
times higher than in non-rejecting controls. Moderate but
significant TGF-b1 upregulation was also found in renal
grafts with borderline changes. TGF-b1 expression was also
significantly increased in grafts with CAN compared with
non-rejecting controls. TGF-b1 expression was enhanced 2.1
times during CAN compared with allografts with a normal
morphological pattern. There was no significant difference in
TGF-b1 upregulation between grafts with AR and CAN
although the levels were higher in the former one.
A minority of grafts showed distinct histological pictures
different from AR or CAN processes (recurrence of GN, ATN,
and CsA toxicity, Figure 3). TGF-b1 gene expression was
strongly enhanced in ATN (Po0.001). Mild upregulation of
TGF-b1 mRNA expression was found in allografts with
histologically proven CsA nephrotoxicity and with recurrence
of GN (Po0.05).
Furthermore, we did not observe significant differences of
TGF-b1 expression levels in patients treated with CsA
compared with tacrolimus-treated patients (Table 3).
There was no relation between intragraft TGF-b1 expres-
sion in AR and short-term outcome of rejection (graft failure,
steroid-resistant rejection, and post-rejection creatinine
levels, Figure 4).
TGF-b1 mRNA expression in graft core biopsy correlated
with GFR at the time of biopsy (Figure 5).
18-month follow-up
Renal allograft recipients were followed for 18 months after
initial core biopsy. ROC curve analysis revealed that TGF-b1
mRNA expression over 32 was associated with deteriorated
renal function 18 months after the initial biopsy (GFR
o0.8 ml/s) demonstrating 77% sensitivity and 39% specifi-
city. The area under the curve was 0.57. Enhanced TGF-b1
gene expression (TGF-b1/hypoxanthin-guanin-phosphoribosyl
-transferase (HPRT) house-keeping gene expression ratio
over 32) in the initial biopsy implied an increased risk for
renal dysfunction 18 months later in patients with CAN
(odds ratio 9.9 (P¼ 0.002) vs 3.2 for low TGF-b mRNA
expression). The GFR 18 months after initial core biopsy was
significantly lower in patients with CAN and enhanced TGF-
b1 gene expression compared to the patients with CAN
and low TGF-b1 mRNA expression (Po0.05). There
were insignificant trends towards inferior 18-months renal
Table 3 | TGF-b1 gene expression in recipients with immu-
nosuppression based on cyclosporine and tacrolimus
TGFb mRNA expression
(ratio to housekeeping
gene) median (range) Pa
Borderline changes
CsA (n=7) 18.51 (7.73–38.05) NS
Tac (n=8) 25.97 (16.17–93.73)
Acute rejection
CsA (n=11) 34.06 (0.67–72.78) NS
Tac (n=12) 28.69 (12.60–113.77)
ATN
CsA (n=7) 35.26 (14.57–48.35) NS
Tac (n=6) 26.37 (5.52–59.71)
CAN
CsA (n=35) 24.68 (2.58–95.67) NS
Tac (n=6) 22.25 (9.07–64.68)
No significant differences in TGF-b1 gene expression for CsA- and Tac-treated
patients with different causes of graft dysfunction were seen.
ATN, acute tubular necrosis – delayed graft function; CAN, chronic allograft
nephropathy; CsA tox, cyclosporine A toxicity; Tac, tacrolimus; TGF-b, transforming
growth factor-b.
aStatistical analysis was performed with Mann–Whitney test. NS, not significant.
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Figure 4 | The effect of intragraft TGF-b1 expression on
short-term outcome of acute rejection. TGF-b1 mRNA expression
did not differ between the groups of steroid-resistant acute rejection
and other acute rejections. Serum creatinine at the time of biopsy
and 1, 6, 12, and 18 months after the biopsy did not differ between
the groups of steroid-resistant acute rejection and other acute
rejections.
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Figure 5 | The association of renal function at the time of biopsy
with TGF-b1 mRNA expression. Kidney graft function was
quantified by estimated GFR.
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function in other diagnostic groups: borderline changes
(odds ratio 2.1 for high expression vs. 0.5 for low expression)
and AR (odds ratio 3.4 vs. 2.1), all compared with graft
outcome of non-rejecting control patients with low TGF-b1
mRNA expression (baseline category). Similarly, there was an
insignificant trend towards inferior outcome in patients with
enhanced TGF-b1 expression also in the group of non-
rejecting controls (odds ratio 4.2). However, we could not
demonstrate any effect of TGF-b1 expression on renal graft
function 18 months later in patients with ATN (odds ratio
0.5 for high expression vs 0.6 for low expression) and CsA
toxicity (odds ratio 4.2 for high expression vs 6.3 for low
expression) (Table 4).
DISCUSSION
Advances in immunosuppressive therapy and patient care
have resulted in considerably improved 1-year patient and
renal allograft survival rates following transplantation.1
Despite this remarkable improvement, the fate of trans-
planted kidney grafts remains unchanged in the long term:
most kidney grafts have been lost in the poorly understood
process of CAN. Several risk factors, both alloantigen
dependent and independent have been identified, including
the number of human leukocyte antigen mismatches,
ischemia/reperfusion injury, number and severity of rejection
episodes, cytomegalovirus infection, long-term CsA treat-
ment, etc., whereby AR is one of the most important risk
factors for the development of CAN.2 The pathogenic
mechanisms of AR related to the development of CAN have
not been clearly established to date. Characteristic patho-
logical features of CAN include interstitial fibrosis, glomerular
changes, arterial intimal thickening, and tubular atrophy.5,6
Recent studies have focused attention to TGF-b1 as an inducer
or regulator of fibrosis resulting in CAN.7–9 TGF-b1 is a potent
profibrogenic cytokine, probably because of the regulatory
effects on macrophage functions and regulation of extra-
cellular matrix components expression.12–14 TGF-b1 expres-
sion is upregulated during CAN 20–22 and its tissue expression
correlates with chronic transplant vasculopathy.27 Based on
these findings, we postulate that intragraft overexpression of
TGF-b1 may be triggered by acute rejection. The ensuing
tissue fibrosis induced by TGF-b1 overexpression leads to renal
allograft dysfunction.
To study the role of TGF-b1 in kidney allograft rejections,
we examined intragraft TGF-b1 mRNA expression in kidney
biopsy specimens and correlated it with morphological
findings. We believe that the homogeneity of these results
confirms reproducibility of real-time RT-PCR as the method
of choice to study the role of cytokines and growth factors
gene expression in kidney allograft rejection despite the fact
that TGF-b1 mRNA expression did not correlate with TGF-
b1 protein expression, as determined by immunohistochem-
istry. Both methods are semiquantitative, which may have
been why the correlation coefficient did not reach the level of
significance and there was only a trend toward increased
TGF-b1 protein expression in patients with higher TGF-b1
mRNA expression. RT-PCR analysis revealed low expression
levels of TGF-b1 mRNA in kidney allografts with normal
histological findings (most of them were carried out as
protocol biopsies). In contrast, AR and CAN have been
associated with remarkable upregulation of TGF-b1 mRNA
expression. Many groups have demonstrated increased TGF-
b1 expression in kidney tissue during CAN either by
immunohistochemical analysis or RT-PCR.20–22 In the
present study, we show that TGF-b1 mRNA is also
upregulated significantly during AR of kidney allografts.
Our results are further supported by overexpression of TGF-
b1 protein in a limited immunohistochemical study (five
biopsies with AR) reported by Shihab et al.28 On the other
hand, our results obtained from the largest cohort of kidney
transplant recipients are in contradiction with other RT-PCR
studies describing induction of TGF-b1 mRNA only during
CAN.20,29 In our study, there was no significant difference in
TGF-b1 mRNA upregulation between AR and CAN groups,
although the level was higher in AR. Nevertheless, TGF-b1
mRNA expression level in the CAN group may have been
affected by the significantly higher use of ACE inhibitors in
this group of patients.
We detected enhanced intrarenal TGF-b1 mRNA expres-
sion during AR and moderate TGF-b1 upregulation in
kidney allograft tissue during borderline changes. These data
are in line with the immunohistochemical studies of Hadley
et al.,17–19 who showed high TGF-b1 expression to be
associated with high expression of aEb7 integrin as a basis
for cytolysis of renal tubular cells. Like other authors,30 we
postulate that TGF-b1 upregulation during AR (probably
because of the activity of allograft infiltrating cells or
activation of renal tubular cells) is followed by cytolysis
and renal tissue destruction. Long-term TGF-b1 production
Table 4 | The effect of intragraft TGF-b1 mRNA overexpres-
sion on outcome
Variable
Odds
ratio
95% confidence
interval Pa
Non Rx, TGF-b1p32 (n=28) 1.00 — —
Non Rx, TGF-b1432 (n=3) 4.20 (0.34, 52.9) 40.1
Borderline changes, TGF-b1p32
(n=11)
0.53 (0.09, 3.00) 40.1
Borderline changes, TGF-b1432
(n=4)
2.10 (0.25, 17.5) 40.1
Acute Rx, TGF-b1p32 (n=12) 2.10 (0.53, 8.41) 40.1
Acute Rx, TGF-b1432 (n=13) 3.38 (0.06, 13.3) 0.098
CAN, TGF-b1p32 (n=30) 3.17 (1.08, 9.3) 0.040
CAN, TGF-b1432 (n=18) 9.85 (2.25, 43.2) 0.002
ATN, TGF-b1p32 (n=9) 0.60 (0.1, 3.5) 40.1
ATN, TGF-b1432 (n=5) 0.53 (0.05, 5.4) 40.1
CsA toxicity, TGF-b1p32 (n=8) 6.30 (1.06, 37.8) 0.046
CsA toxicity, TGF-b1432 (n=3) 4.20 (0.74, 5.4) 40.1
TGF-b1 overexpression (ratio TGF-b1 vs HPRT over 32) in initial biopsies increased
the risk (odds ratio) for renal allograft dysfunction (GFR o0.8 ml/s) 18 months later
in patients with CAN.
aP-values comes from Fisher’s exact test.
Acute Rx, acute rejection; ATN, acute tubular necrosis – delayed graft function; CAN,
chronic allograft nephropathy; CsA tox, cyclosporine A toxicity; non Rx, non-
rejecting controls; TGF-b, transforming growth factor-b.
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might result in kidney allograft tissue remodelling as a
hallmark of CAN. However, we have not demonstrated an
association between TGF-b1 mRNA levels during AR and
short-term graft function outcome. Thus, we could not
confirm results of Eikmans et al.31 reporting a protective
effect of TGF-b1 overexpression during AR that reduces the
extent of later CAN. Moreover, our results showed that the
enhanced TGF-b1 mRNA expression might be associated
with an increased risk for graft dysfunction in some cohorts
of patients, including patients with AR. TGF-b1 may induce
cytolysis of renal tubules,17–19,30 thus we assume its over-
expression during AR to be associated with later tissue
remodelling.
Strong upregulation of intragraft TGF-b1 expression
was also found in the group with ATN. Similar results
were obtained in immunohistochemical studies.32 ATN is
also a major risk factor of CAN. It has been speculated
that allograft injuries because ofischemia/reperfusion injury
and AR cause overexpression of TGF-b1 enhancing inter-
stitial fibrosis by promoting extracellular matrix accumula-
tion.22 These results suggest mechanisms by which risk
factors such as ischemia/reperfusion injury and AR might
contribute to CAN. Nevertheless, we did not demonstrate
that high TGF-b1 expression during ATN raises the risk for
graft dysfunction within 18 months since transplantation.
Such an effect of enhanced TGF-b1 expression may manifest
itself later.
In addition to ischemia/reperfusion injury and AR, CsA is
reported to stimulate TGF-b1 expression.33–34 In our study,
TGF-b1 mRNA expression level within the kidney grafts of
CsA-treated patients did not differ from that in tacrolimus-
treated patients. This findings are consistent with other
reports demonstrating that tacrolimus also stimulates TGF-
b1 gene expression.25–26
The essential sense of studies concerning the intragraft
gene expression is not to substitute the conventional
diagnostic tools as histology or clinical data. They are able
to contribute to understanding the complex immunological
processes occurring in kidney graft after transplantation and
in long-term follow-up. They can also reveal the additional
risk factors for graft dysfunction. The main limitation of our
study is the number of included biopsies. Although our
results came from the largest cohort of kidney transplant
recipients published so far, the numbers of samples in
individual diagnostic groups remained to be low. This fact
may limit results of statistical analyses. In our study, we used
ROC analysis to determine the cutoff value for TGF-b1
mRNA expression. The low area under the curve in this ROC
analysis indicates its lower predictive value, which however
did not influence conclusions we drawn.
In conclusion, our results confirm the importance of
intragraft TGF-b1 mRNA upregulation during many patho-
logical processes leading to late graft dysfunction. TGF-b1
mRNA upregulation in CAN predicts poor renal graft
function within the 18-month follow-up. Alternative thera-
peutic strategies directed towards downregulation of TGF-b1
expression may decrease the risk for late renal allograft
dysfunction in the future.
Table 5 | Renal allograft histological diagnosis
Biopsies (n=174)
Recipients (n=144) Protocol (n=57) Diagnostic (n=117)
TGF-b1 mRNA expression analysis
Non-rejecting controls b Rx n=1 Non-rejecting controls b Rx n=14 Excludeda
CAN n=28 Acute Rx n=25
GN n=1 CAN n=20
CsA tox n=3 GN n=3
ATN n=14
CsA tox n=8
n=24 n=33 n=7 n=84 n=26
Biopsies (n=109)
Recipients (n=84) Protocol Diagnostic Excluded
b
TGF-b1 protein expression analysis
Non Rx n=5 Non Rx n=7
CAN n=11 b Rx n=10
Acute Rx n=16
CAN n=10
GN n=4
ATN n=10
CsA tox n=8
n=16 n=65 n=28
aSamples were excluded from the study because of a combination of causes of graft dysfunction.
bSamples were excluded from the immunohistochemical analysis because of an insufficient quantity of cortex for examination.
acute Rx, acute rejection; ATN, acute tubular necrosis – delayed graft function; b Rx, borderline changes; CAN, chronic allograft nephropathy; CsA tox, cyclosporine A toxicity;
GN, glomerulonephritis recurrence; non Rx, non-rejecting controls; TGF-b, transforming growth factor-b.
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MATERIALS AND METHODS
Subjects
A total of 174 allograft biopsies performed between November 2001
and July 2003 were obtained from 144 renal allograft recipients,
from 4 days up to 7 years after transplantation. Fifty-seven core
biopsies were performed 12 months after transplantation in
recipients with stable graft function (serum creatinine
o200 mmol/l) according to protocol, the remaining 117 biopsies
were performed to clarify the etiology of graft dysfunction (Table 5).
Immunosuppression consisted of a triple therapy regimen in most
kidney graft recipients (n¼ 128). CsA was administered in 86
recipients (10 in combination with azathioprin and 76 with
mycophenolate mofetil. Forty-two recipients were treated by
tacrolimus, six from them were kept on a combination with
azathioprin and the remaining 36 on tacrolimus with mycopheno-
late mofetil. Nine patients were treated with sirolimus and seven
with azathioprin. Histopathological signs of CsA toxicity were
assessed on the basis of previously defined criteria.5
All patients underwent regular clinical follow-up, renal function
was quantified by the analysis of serum creatinine 1 month before
biopsy, on the day of biopsy and at 1, 6, 12, and 18 months after
renal biopsy and by the GFR (estimated using the Cockcroft–Gault
formula) at the time of biopsy and 18 months later.
All patients gave their written inform consent to participate in
the study. The Ethics Committee of the Institute for Clinical and
Experimental Medicine in Prague approved the study protocol.
Renal biopsy
All biopsies were carried out by a 14 G tru-cut needle (Uni-Cut
Nadeln, Angiomed, Germany) guided by ultrasound (Toshiba,
Power Vision 6000, Japan). Most of the renal tissue taken by core
biopsy was used for routine histology performed by standard
method. Small portions of renal tissue from the cortex or
juxtamedulary zone were immediately frozen in liquid nitrogen
and stored at 801C.
The biopsies were divided into groups according to the
histological diagnosis, and TGF-b1 gene expression within renal
tissue was compared among the groups. Histological sections and
specimen adequacy for immunohistochemical examination were
evaluated using the Banff criteria.5 Protocol biopsies or biopsies
taken from kidney grafts with only a temporary elevation of serum
creatinine with spontaneous improvement of renal function that
showed a normal histological pattern of renal tissue served as a non-
rejecting control group. Twenty-six biopsies were excluded because
of a combination of causes of graft dysfunction, while the leading
cause could not be identified (Table 5).
Immunohistochemistry
In 109 renal biopsies obtained from 84 recipients, immunohisto-
logical evaluation for TGF-b1 was performed. Twenty-eight biopsies
were excluded because of an insufficient quantity of cortex
(glomeruli) for examination. The total number of biopsies included
in the study was 81 (Table 5).
Immunohistochemistry was performed on 4 mm-thick paraffin
sections of kidney biopsies. Slides were deparaffinized in xylene and
rehydrated in graded ethanols. After deparaffinization and re-
hydratation, slides were cooked in a microwave oven (twice for
2 min and then twice at a 5-min interval for 2 min at 750 W) using a
0.01 M citrate buffer pH 6.0 for target retrieval. Endogenous
peroxidase was blocked by 0.3% H2O2 in 70% methanol for
30 min. Endogenous biotin was blocked using a biotin blocking
system (DakoCytomation, Denmark). Tissue was then preincubated
in a protein mixture to prevent unspecific binding and Fc receptor
binding (10% bovine serum with 20% porcine serum in phosphate-
buffered saline). Primary antibody, which reacts with active and
latent TGF-b1 (anti-human TGF-b1, clone TB 21, Biosource Int.,
CA, USA) was applied for 30 min, diluted at the concentration of
0.5 mg/100 ml. The step with monoclonal antibody was omitted on
negative control slides. Detection of monoclonal antibody was done
using a horseradish peroxidase-labelled streptavidin biotin system
(LSAB Plus Kit, DakoCytomation) following company protocol.
Finally, specimens were incubated with Dako Liquid DABþ
Substrate-Chromogen System for 5 min and counterstained with
Harris’s hematoxylin before they were embedded in Entellan (both
from Merck, Germany).
Semiquantitative scoring method (scale 0–3) was used for
description of TGF-b1 positivity in six assessed renal structures:
glomeruli, tubuli, peritubular capillaries, intima, intestitium, and
infiltrating cells (Figure 6) as it was described elsewhere.35 The
samples were analyzed by a single investigator in a blinded fashion.
RNA isolation and real-time quantitative RT-PCR
The renal tissue was homogenized, total RNA was extracted using a
StrataPreps Total RNA Microprep Kit (Stratagene, La Jolla, CA,
USA) and reverse transcribed into complementary DNA, as
described elsewhere.36 Briefly, mRNA measurement was performed
using the ABI PRISMs-7700DS System (Applied Biosystems,
Darmstadt, Germany) with 40 cycles of 15-s denaturation at 951C
and a 60-s annealing-extension step at 601C. Gene expression of
HPRT mRNA was used for normalization given by the formula
2DCt . All primers and probes were designed using Primer Express
software (Applied Biosystems) and validated at the Institute of
a b
c d
Figure 6 | Intragraft TGF-b1 protein expression – immunohisto-
logy. Negative staining for TGF-b1 in protocol biopsies 12 months
after transplantation with normal histology are shown in panel (a).
Focal positive staining in glomeruli and a mild positive signal in the
endothelium of peritubular capillaries (b). A dense diffuse positive
signal was seen in panel (c) in the endothelium of peritubular
capillaries in renal allograft with delayed graft function (ATN). Diffuse
positive TGF-b1 staining was shown in panel (d) in a patient with CAN
grade III.
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Medical Immunology, University Medicine Charite´, Berlin,
Germany. Sequences for amplification primers and probes were as
follows: TGF-b1 sense (S) 50-CCCTGCCCCTACATTTGGAG-30,
antisense (AS) 50-CCGGGTTATGCTGGTTGTACA3-0, (probe) 50-C
ACGCAGTACAGCAAGGTCCTGCC-30 and for HPRT (S) 50-AGTC
TGGCTTATATCCAACACTTCG-30, (AS) 50-GACTTTGCTTTCCTT
GGTCAGG-30, (probe) 50-TTTCACCAGCAAGCTTGCGACCTTGA-30.
The amplification primers were designed to span the exon borders
to exclude crossreactivity with genomic DNA. The mean Ct-values
for TGF-b1 and HPRT were calculated from double determinations.
Samples were considered negative if the Ct-values exceeded 40 cycles
and results are presented as median.
Statistics
For comparison of data obtained in different groups, the
Kruskal–Wallis test, the Mann–Whitney test with multiple compari-
sons (Holm’s correction of significance levels), and w2 test with
calculation of adjusted standardized deviates were used. TGF-b1
mRNA expression levels were correlated (Spearman-Rank correla-
tion) with clinical and immunohistological data. Using a ROC
curve, we determined the cutoff points of TGF-b1 mRNA expression
levels with the best combination of sensitivity and specificity that
predicted a normal histological finding in biopsy specimen and that
indicated the renal allograft dysfunction on long-term outcome.
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